Home > Insider Trading > Filing (0001209191-11-021309)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1282660	R Julianna Wood	C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080	Vp, Public Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-03-31	2,500	$0.00	10,953	No	4	A	Direct
Common Stock	Acquisiton	2011-03-31	8,000	$0.00	118,953	No	4	A	Direct
Common Stock	Disposition	2011-03-31	428	$35.18	18,525	No	4	F	Direct
Common Stock	Disposition	2011-04-01	1,078	$35.02	17,447	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2011-03-31	17,500	$0.00	17,500	$35.18

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,500		2021-03-31	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	200	Indirect	Childrens' Trust

Footnotes

Represents a restricted stock award granted to the reporting person. The restricted stock award vests annually over 3 years.
Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones.
Payment of exercise price or tax liability by delivering or withholding securities incident to receipt, exercise or vesting of a security issued in accordance with Rule 16b-3.
Shares sold pursuant to a 10b5-1 plan.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.